Kristian Reich Selected Research

Ustekinumab (CNTO 1275)

2/2024	Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA).
10/2023	Secukinumab versus guselkumab in the complete resolution of ustekinumab-resistant psoriatic plaques: The ARROW study.
3/2022	Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials.
2/2022	Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab.
1/2022	Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis.
1/2021	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
10/2020	Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post-hoc Analysis from a Long-term Clinical Study.
1/2019	Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.
1/2017	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
9/2015	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kristian Reich Research Topics

Disease

129	Psoriasis (Pustulosis Palmaris et Plantaris) 02/2024 - 01/2002
25	Atopic Dermatitis (Atopic Eczema) 04/2024 - 04/2002
16	Infections 11/2023 - 12/2008
13	Neoplasms (Cancer) 11/2023 - 09/2002
9	Inflammation (Inflammations) 04/2024 - 06/2004
8	Psoriatic Arthritis 05/2022 - 06/2007
7	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 08/2021 - 09/2008
6	Eczema 10/2023 - 02/2003
6	Pruritus (Itching) 10/2023 - 07/2011
5	Necrosis 01/2024 - 02/2003
5	Melanoma (Melanoma, Malignant) 07/2012 - 09/2002
4	Skin Neoplasms (Skin Cancer) 11/2023 - 12/2008
4	Respiratory Tract Infections (Respiratory Tract Infection) 12/2022 - 01/2021
4	Hypersensitivity (Allergy) 07/2011 - 02/2003
3	Arthritis (Polyarthritis) 01/2024 - 05/2006
3	Herpes Labialis (Fever Blister) 01/2023 - 01/2008
3	Skin Diseases (Skin Disease) 01/2023 - 01/2017
3	Injection Site Reaction 12/2022 - 02/2018
3	Nasopharyngitis 01/2022 - 01/2021
3	Hypertension (High Blood Pressure) 01/2021 - 07/2012
3	Crohn Disease (Crohn's Disease) 01/2021 - 03/2017
3	Candidiasis (Moniliasis) 01/2021 - 07/2016
3	Rheumatoid Arthritis 02/2014 - 07/2003
2	Myocardial Infarction 09/2023 - 03/2012
2	Body Weight (Weight, Body) 06/2022 - 10/2010
2	Ankylosing Spondylitis 04/2022 - 01/2019
2	Cardiovascular Diseases (Cardiovascular Disease) 03/2022 - 01/2019
2	Headache (Headaches) 01/2022 - 01/2021
2	Pain (Aches) 01/2022 - 01/2017
2	Oral Candidiasis (Thrush) 01/2021 - 01/2021
2	Ulcerative Colitis 02/2020 - 03/2017
2	Drug-Related Side Effects and Adverse Reactions 12/2008 - 07/2007
2	Allergic Contact Dermatitis 12/2003 - 02/2003
1	Atherosclerosis 04/2024

Drug/Important Bio-Agent (IBA)

23	Monoclonal AntibodiesIBA 04/2024 - 10/2005
21	secukinumabIBA 12/2023 - 07/2014
21	Interleukin-17 (Interleukin 17)IBA 10/2023 - 02/2014
19	ixekizumabIBA 12/2023 - 01/2012
18	guselkumabIBA 02/2024 - 07/2015
17	InterleukinsIBA 04/2024 - 01/2002
17	Ustekinumab (CNTO 1275)FDA Link 02/2024 - 05/2008
15	Immunoglobulin A (IgA)IBA 11/2023 - 01/2019
15	Adalimumab (Humira)FDA Link 09/2023 - 09/2008
13	Etanercept (Enbrel)FDA Link 02/2018 - 09/2008
13	Infliximab (Remicade)FDA Link 10/2011 - 10/2005
12	CytokinesIBA 01/2024 - 01/2002
11	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2018 - 01/2002
10	FumaratesIBA 12/2022 - 03/2007
9	Interleukin-23 (Interleukin 23)IBA 11/2023 - 02/2009
8	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2023 - 10/2011
6	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 03/2009
6	AntibodiesIBA 01/2019 - 09/2008
5	Prostaglandins AIBA 09/2023 - 07/2009
5	dupilumabIBA 01/2023 - 02/2020
5	Interleukin-12 (IL 12)IBA 01/2022 - 05/2008
4	Interleukin-13IBA 04/2024 - 01/2019
4	abrocitinibIBA 10/2023 - 01/2022
4	baricitinibIBA 10/2023 - 12/2020
4	bimekizumabIBA 01/2021 - 01/2021
4	Tumor Necrosis Factor InhibitorsIBA 01/2021 - 03/2008
4	Proteins (Proteins, Gene)FDA Link 07/2012 - 09/2002
4	Interleukin-16 (Interleukin 16)IBA 01/2011 - 04/2002
3	tralokinumabIBA 04/2024 - 10/2022
3	omega-Chloroacetophenone (Mace)IBA 11/2023 - 03/2012
3	Janus Kinase 1IBA 10/2023 - 01/2020
3	apremilastIBA 01/2023 - 07/2015
3	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2022 - 10/2011
3	TabletsIBA 01/2022 - 03/2007
3	upadacitinibIBA 01/2022 - 01/2020
3	ChemokinesIBA 01/2021 - 07/2003
3	Immunoglobulin E (IgE)IBA 01/2019 - 07/2011
3	calcipotriene (calcipotriol)FDA LinkGeneric 06/2017 - 08/2014
3	Dimethyl FumarateIBA 07/2009 - 03/2007
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 02/2007 - 09/2002
2	brodalumabIBA 02/2024 - 03/2022
2	Interleukin-23 Subunit p19IBA 09/2023 - 08/2021
2	risankizumabIBA 09/2023 - 01/2019
2	spirulanIBA 01/2023 - 01/2016
2	sonelokimabIBA 10/2022 - 01/2021
2	Janus KinasesIBA 01/2022 - 01/2021
2	Janus Kinase InhibitorsIBA 06/2021 - 01/2021
2	Filaggrin ProteinsIBA 01/2021 - 01/2011
2	AerosolsIBA 06/2017 - 01/2017
2	betamethasone-17,21-dipropionate (betamethasone dipropionate)FDA LinkGeneric 06/2017 - 01/2017
2	Acyclovir (Aciclovir)FDA LinkGeneric 01/2016 - 01/2008
2	Omalizumab (Xolair)FDA Link 07/2013 - 07/2011
2	AllergensIBA 07/2011 - 02/2003
2	AutoantibodiesIBA 07/2011 - 02/2007
2	Glutathione Transferase (Glutathione S-Transferase)IBA 01/2011 - 01/2007
2	efalizumab (Raptiva)FDA Link 01/2010 - 06/2006
2	PPAR gammaIBA 02/2007 - 09/2002
2	LigandsIBA 06/2004 - 09/2002
2	PPAR alphaIBA 06/2004 - 09/2002
1	Biomarkers (Surrogate Marker)IBA 04/2024
1	mirikizumabIBA 09/2023

Therapy/Procedure

54	Therapeutics 01/2024 - 08/2003
8	Biological Therapy 12/2021 - 05/2008
2	Aftercare (After-Treatment) 01/2023 - 12/2019
2	Contraindications 01/2022 - 07/2007
2	Phototherapy (Light Therapy) 01/2019 - 02/2017